BLA 761427 · Lib Therapeutics, Inc.
Lerochol
Lerodalcibep-Liga · Injection
NovelCDER novel approval, Dec 12, 2025: To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise
Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 12, 2025
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
13
11 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise
Therapeutic areas: Cardiovascular and metabolic · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Lerodalcibep" as an intervention, any sponsor and status, largest first.
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionPivotal-lookingStatus unknown
LIB Therapeutics LLCIndustry
NCT04798430 · 2,000 participants (planned) · Start Dec 3, 2020 · Primary completion Jul 30, 2025
Drug: lerodalcibep · For: Cardiovascular Disease With Mention of Arteriosclerosis; Elevated Cholesterol; Familial Hypercholesterolemia
Sites: Evanston, Illinois; Cincinnati, Ohio; New Delhi, India · 12 sites in all
- Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C ReductionPivotal-lookingStatus unknown
LIB Therapeutics LLCIndustry
NCT04797247 · 900 participants (planned) · Start Apr 22, 2021 · Primary completion Nov 15, 2023
Drug: lerodalcibep · For: Cardiovascular Diseases; Hyper-LDL-cholesterolemia
Sites: Cincinnati, Ohio · 3 sites in all
- Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C ReductionPivotal-lookingStatus unknown
LIB Therapeutics LLCIndustry
NCT04806893 · 900 participants (planned) · Start Apr 22, 2021 · Primary completion Nov 15, 2023
Drug: lerodalcibep · For: Cardiovascular Risk Factor; Cardiovascular Diseases; Cardiovascular Stroke and 1 more
Sites: Cincinnati, Ohio; New Delhi, India; Jerusalem, Israel · 6 sites in all
- Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C ReductionPivotal-lookingCompleted
LIB Therapeutics LLCIndustry
NCT04797104 · 478 participants · Start Apr 22, 2021 · Primary completion Jul 30, 2023
Drug: lerodalcibep · For: Heterozygous Familial Hypercholesterolemia
Sites: Cincinnati, Ohio; Jerusalem, Israel; Petah Tikva, Israel · 7 sites in all
- A Study on Efficacy and Safety of HST101 in Chinese Patients with HypercholesterolemiaPivotal-lookingRecruiting
Hasten Biopharmaceutical Co., Ltd.Industry
NCT06568471 · 210 participants (planned) · Start Nov 16, 2024 · Primary completion Feb 2026
Drug: Lerodalcibep; matching placebo · For: Hypercholesterolemia; Dyslipidemias; Primary Hypercholesterolemia and 4 more
Sites: Beijing, China; Guangzhou, China; Shijiazhuang, China · 18 sites in all
- Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD PatientsPivotal-lookingCompleted
LIB Therapeutics LLCIndustry
NCT04790513 · 204 participants · Start Apr 22, 2021 · Primary completion Sep 30, 2022
Drug: lerodalcibep; evolocumab and 1 more · For: Hypercholesterolemia; Cardiovascular Diseases
Sites: Cincinnati, Ohio · 3 sites in all
- Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD PatientsPivotal-lookingCompleted
LIB Therapeutics LLCIndustry
NCT05004675 · 166 participants · Start Jun 20, 2022 · Primary completion May 30, 2024
Drug: lerodalcibep; Inclisiran · For: Hypercholesterolemia; Atherosclerotic Ischemic Disease
Sites: Nantes, France; Marseille, France; Heidelberg, Germany · 7 sites in all
- Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHPivotal-lookingEnrolling by invitation
LIB Therapeutics LLCIndustry
NCT07102511 · 150 participants (planned) · Start Jul 20, 2026 · Primary completion Jul 31, 2028
Drug: lerodalcibep 300 mg Monthly SC · For: Familial Hypercholesterolemia - Heterozygous
Sites: Cincinnati, Ohio; Jerusalem, Israel; Christchurch, New Zealand · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial.
Raal F, Fourie N, Scott R, et al. · Eur Heart J 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.
Klug EQ, Llerena S, Burgess LJ, et al. · JAMA Cardiol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials.
Mulligan MD, Gandhi RS, Vishwakarma R, et al. · J Clin Lipidol 2026 · Systematic Review, Meta-Analysis
- Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.
Raal FJ, Mehta V, Kayikcioglu M, et al. · Lancet Diabetes Endocrinol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.
Raal FJ, Fourie N, Scott R, et al. · JAMA Cardiol 2026 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
Sponsor: Lib Therapeutics, Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.